CAS 1454846-35-5 appears in our catalog under these names: PF–06463922, Lorlatinib (PF-6463922), Lorlatinib/ 99.93% (existing batch purity), Lorlatinib, Lorlatinib, 98%. Offered by: GLPBio, Chemat Brand, TargetMol, Biosynth, Thermo Scientific (Acros). Available pack sizes: 5mg, on request, 1g, 2mg, 10mg, 25mg, 50mg, 100mg.
Lorlatinib is a cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer. It has a role as an antineoplastic agent and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It is a nitrile, a member of benzamides, a member of pyrazoles, an aromatic ether, a cyclic ether, an organic heterotetracyclic compound, an aminopyridine, an azamacrocycle and a member of monofluorobenzenes.
Source: ChEBI
| Molecular formula | C21H19FN6O2 |
|---|---|
| Molecular weight | 406.4 g/mol |
| IUPAC name | (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile |
| InChIKey | IIXWYSCJSQVBQM-LLVKDONJSA-N |
| SMILES | C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C |
Computed by PubChem (NCBI)